著者

Junko Naito Hiroshige Ohashi Michiya Ohno Masafumi Sugiyama Kazuyoshi Hayakawa Akihisa Kunishima Nobuyuki Takada Tatsuya Kariya Koshi Goto Hisato Takatsu Toshiki Ohira Koji Nakahara Ichijiro Murata Shingo Minatoguchi Gakuro Yoshida Hiroyuki Okura Shinya Minatoguchi

出版者

The Japanese Circulation Society

雑誌

Circulation Reports (ISSN:24340790)

巻号頁・発行日

vol.1, no.11, pp.508-516, 2019-11-08 (Released:2019-11-08)

参考文献数

31

被引用文献数

2

---

Background:Levocarnitine has been reported to improve the left ventricular (LV) systolic function and decrease LV hypertrophy in hemodialysis (HD) patients. Its effect on LV diastolic dysfunction, however, has not yet been clarified.Methods and Results:HD patients (n=88) were given levocarnitine i.v. 1,000 mg for 12 months at the end of every dialysis session through the dialysis circuit of the venous site. LV ejection fraction (EF), E/A, E/e’, left atrial volume index (LAVI) and LV mass index (LVMI) were measured before and 3, 6, 9, and 12 months after the start of levocarnitine on echocardiography. We regarded E/A≤0.8, E/e’>14 and LAVI>34 mL/m2as LV diastolic dysfunction, and LVEF<55% as LV systolic dysfunction. We also investigated the effect of levocarnitine on HFpEF. Plasma brain natriuretic peptide, total carnitine, free carnitine, and acyl-carnitine and biochemistry parameters were measured. Levocarnitine significantly improved LV diastolic function in HD patients with LV diastolic dysfunction, but did not affect LV diastolic function in those with normal LV diastolic function. Levocarnitine significantly improved HFpEF. Levocarnitine significantly improved the LV systolic function in HD patients with LV systolic dysfunction but did not affect the LV systolic function in those with normal LV systolic function. Levocarnitine significantly decreased LVMI and increased plasma total, free, and acyl-carnitine.Conclusions:Levocarnitine ameliorates LV diastolic as well as LV systolic dysfunction in HD patients.